Kairasec (Candesartan Cilexetil)

Candesartan cilexetil selectively blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing vasoconstriction and aldosterone release, which results in vasodilation, reduced sodium retention, and lower blood pressure.

The appropriate dose of Kairasec is determined by the prescribing physician based on the individual’s clinical condition, response to therapy, and any concomitant medications. Specific dosing regimens are not provided here.

Candesartan cilexetil is generally contraindicated in pregnancy, especially in the second and third trimesters, due to potential fetal harm. Limited data are available for breastfeeding; use only if the potential benefit outweighs the risk.

To order Kairasec, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Kairasec (an ARB) offers similar blood‑pressure‑lowering efficacy to ACE inhibitors but with a lower incidence of cough. Unlike some calcium‑channel blockers, it does not cause reflex tachycardia, and it provides renal protective benefits in diabetic patients.

Store Kairasec at room temperature, below 25 °C, in the original container. Protect the tablets from moisture, light, and excessive heat to maintain stability and potency.

Kairasec is taken orally, usually as a tablet, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the dose should be taken once daily or in divided doses.

Serious adverse effects include angioedema, severe hypotension, acute renal failure, and rare cases of hepatic injury. Prompt medical attention is required if any of these symptoms develop.

Kairasec should be avoided in patients with known hypersensitivity to candesartan, severe hepatic impairment, pregnancy (especially second/third trimester), and in those taking contraindicated drug combinations such as ACE inhibitors or aliskiren in diabetic patients.